Ken Griffin Sarepta Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $4.3 Million - $5.42 Million	-34,600 Reduced 17.11%	167,600 $20.9 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $8.72 Million - $12.6 Million	-76,900 Reduced 27.55%	202,200 $31.9 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $23 Million - $34.7 Million	-245,300 Reduced 46.78%	279,100 $36.1 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $14.4 Million - $26.7 Million	214,400 Added 69.16%	524,400 $50.6 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $9.46 Million - $11.4 Million	92,300 Added 42.4%	310,000 $37.6 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $4.04 Million - $5.97 Million	-38,000 Reduced 14.86%	217,700 $24.9 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $15.9 Million - $21.1 Million	135,200 Added 112.2%	255,700 $35.2 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $3.92 Million - $5.14 Million	38,900 Added 47.67%	120,500 $15.6 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $1.37 Million - $2.16 Million	18,100 Added 28.5%	81,600 $9.02 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.